Tietze LF - Search Results

1

Galactose-modified duocarmycin prodrugs as senolytics.

Guerrero A, Guiho R, Herranz N, Uren A, Withers DJ, Martínez-Barbera JP, Tietze LF, Gil J. Guerrero A, et al. Among authors: tietze lf. Aging Cell. 2020 Apr;19(4):e13133. doi: 10.1111/acel.13133. Epub 2020 Mar 16. Aging Cell. 2020. PMID: 32175667 Free PMC article.

2

Duocarmycin-based prodrugs for cancer prodrug monotherapy.

Tietze LF, Schuster HJ, Schmuck K, Schuberth I, Alves F. Tietze LF, et al. Bioorg Med Chem. 2008 Jun 15;16(12):6312-8. doi: 10.1016/j.bmc.2008.05.009. Epub 2008 May 7. Bioorg Med Chem. 2008. PMID: 18524605

3

Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy.

Tietze LF, Schuster HJ, Krewer B, Schuberth I. Tietze LF, et al. J Med Chem. 2009 Jan 22;52(2):537-43. doi: 10.1021/jm8009102. J Med Chem. 2009. PMID: 19143570

4

Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.

Tietze LF, Krewer B. Tietze LF, et al. Chem Biol Drug Des. 2009 Sep;74(3):205-11. doi: 10.1111/j.1747-0285.2009.00856.x. Epub 2009 Jul 29. Chem Biol Drug Des. 2009. PMID: 19660031

5

Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy.

Tietze LF, Müller M, Duefert SC, Schmuck K, Schuberth I. Tietze LF, et al. Chemistry. 2013 Jan 28;19(5):1726-31. doi: 10.1002/chem.201202773. Epub 2012 Dec 7. Chemistry. 2013. PMID: 23225610

6

Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity.

Schuster HJ, Krewer B, von Hof JM, Schmuck K, Schuberth I, Alves F, Tietze LF. Schuster HJ, et al. Among authors: tietze lf. Org Biomol Chem. 2010 Apr 21;8(8):1833-42. doi: 10.1039/b925070k. Org Biomol Chem. 2010. PMID: 20449487

7

Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.

Tietze LF, Schmuck K. Tietze LF, et al. Curr Pharm Des. 2011;17(32):3527-47. doi: 10.2174/138161211798194459. Curr Pharm Des. 2011. PMID: 22074425 Review.

8

Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.

Tietze LF, Krewer B. Tietze LF, et al. Anticancer Agents Med Chem. 2009 Mar;9(3):304-25. doi: 10.2174/1871520610909030304. Anticancer Agents Med Chem. 2009. PMID: 19275523 Review.

9

Glycosidic prodrugs of highly potent bifunctional duocarmycin derivatives for selective treatment of cancer.

Tietze LF, von Hof JM, Müller M, Krewer B, Schuberth I. Tietze LF, et al. Angew Chem Int Ed Engl. 2010 Sep 24;49(40):7336-9. doi: 10.1002/anie.201002502. Angew Chem Int Ed Engl. 2010. PMID: 20799305 No abstract available.

10

A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs.

Tietze LF, Lieb M, Herzig T, Haunert F, Schuberth I. Tietze LF, et al. Bioorg Med Chem. 2001 Jul;9(7):1929-39. doi: 10.1016/s0968-0896(01)00098-0. Bioorg Med Chem. 2001. PMID: 11425596

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

130 results

Search Page